Previous Close | 9.40 |
Open | 9.40 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 9.40 - 9.40 |
52 Week Range | 3.00 - 20.00 |
Volume | |
Avg. Volume | 4 |
Market Cap | 162.358M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Niche Companies in, Technology, Transportation, Biotech, Mining, MedTech, Logistics, and HealthcareMIAMI, Oct. 25, 2022 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 43rd Emerging Growth Conference on October 26, 2022. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong manageme
RetinalGeniX Technologies Invites Individual and Institutional Investors, Advisors, and Analysts, to Attend its Real-Time, Interactive Presentation at The Emerging Growth ConferencePETALUMA, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies, Inc. OTCQB: RTGN to Present at the Emerging Growth Conference. RetinalGeniX Technologies, Inc. (RTGN) is pleased to announce that it has been invited to present a 30 - minute investor overview at the Emerging Growth Conference on Wednesday,
Appointment Expected to Support Initiatives to Improve Population Health Management and the Company’s Planned Listing Upgrade from OTCBQB to NASDAQ Vinay Mehindru joins Retinalgenix Board of Directors Vinay Mehindru, MD, MBA PETALUMA, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- RetinalGenix™ Technologies, Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), announced today the appointment of Vinay Mehindru, MD, MBA to the RetinalGenix Technologies, Inc. Board of Directors. Dr. Mehindru is a multi-